ARGI Investment Services LLC Purchases 591 Shares of Eli Lilly and Company (NYSE:LLY)

ARGI Investment Services LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.0% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 12,380 shares of the company’s stock after acquiring an additional 591 shares during the quarter. ARGI Investment Services LLC’s holdings in Eli Lilly and were worth $2,860,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Eli Lilly and by 6.7% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 150,896 shares of the company’s stock valued at $34,634,000 after buying an additional 9,531 shares during the period. Mission Wealth Management LP lifted its holdings in shares of Eli Lilly and by 2.3% during the 2nd quarter. Mission Wealth Management LP now owns 5,449 shares of the company’s stock valued at $1,251,000 after buying an additional 124 shares during the period. Harvest Fund Management Co. Ltd lifted its holdings in shares of Eli Lilly and by 8.7% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 5,461 shares of the company’s stock valued at $1,261,000 after buying an additional 435 shares during the period. Crewe Advisors LLC lifted its holdings in shares of Eli Lilly and by 9.3% during the 2nd quarter. Crewe Advisors LLC now owns 590 shares of the company’s stock valued at $135,000 after buying an additional 50 shares during the period. Finally, Fiera Capital Corp lifted its holdings in shares of Eli Lilly and by 23.2% during the 2nd quarter. Fiera Capital Corp now owns 18,801 shares of the company’s stock valued at $3,086,000 after buying an additional 3,537 shares during the period. 81.79% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have recently commented on the company. Wells Fargo & Company upped their price objective on Eli Lilly and from $270.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 4th. Bank of America upped their price objective on Eli Lilly and from $285.00 to $300.00 and gave the stock a “buy” rating in a research note on Thursday, December 16th. Berenberg Bank upped their price objective on Eli Lilly and from $270.00 to $305.00 and gave the stock a “buy” rating in a research note on Monday, December 20th. Sanford C. Bernstein upped their price objective on Eli Lilly and from $250.00 to $300.00 and gave the stock a “market perform” rating in a research note on Monday, January 3rd. Finally, Barclays upped their price objective on Eli Lilly and from $280.00 to $325.00 and gave the stock an “overweight” rating in a research note on Monday, December 20th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $287.74.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 3,570 shares of the firm’s stock in a transaction dated Monday, December 27th. The shares were sold at an average price of $279.53, for a total value of $997,922.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 424,939 shares of company stock valued at $114,549,362. 0.13% of the stock is owned by insiders.

Shares of NYSE:LLY opened at $244.12 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.02 and a debt-to-equity ratio of 1.95. Eli Lilly and Company has a 12 month low of $178.58 and a 12 month high of $283.90. The company has a 50-day moving average price of $260.43 and a 200 day moving average price of $250.68. The company has a market cap of $233.52 billion, a price-to-earnings ratio of 37.21, a PEG ratio of 1.86 and a beta of 0.36.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Monday, October 25th. The company reported $1.94 EPS for the quarter, missing the Zacks’ consensus estimate of $1.98 by ($0.04). The business had revenue of $6.77 billion during the quarter, compared to the consensus estimate of $6.64 billion. Eli Lilly and had a net margin of 21.52% and a return on equity of 111.51%. The firm’s revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.54 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 8.18 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 10th. Shareholders of record on Tuesday, February 15th will be paid a $0.98 dividend. The ex-dividend date is Monday, February 14th. This represents a $3.92 annualized dividend and a yield of 1.61%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.85. Eli Lilly and’s dividend payout ratio (DPR) is presently 51.83%.

Eli Lilly and Profile

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Featured Article: What are the reasons investors use put options?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.